Skip to main content

Patricia Bogdanov Baruj

Institutions of which they are part

Postdoctoral researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Patricia Bogdanov Baruj

Institutions of which they are part

Postdoctoral researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Projects

Mediadores inflamatorios en la retinopatía diabética: investigación traslacional para nuevos abordajes terapéuticos

IP: Cristina Hernández Pascual
Collaborators: Ana Boixadera Espax, Alejandra Planas Vilaseca, Patricia Bogdanov Baruj
Funding agency: Instituto de Salud Carlos III
Funding: 154275
Reference: PI16/00541
Duration: 01/01/2017 - 31/07/2020

Desarrollo de un tratamiento tópico (colirio) para la retinopatía diabética basado en la señalización de la vía del GLP-1

IP: Rafael Simó Canonge
Collaborators: Cristina Hernández Pascual, Patricia Bogdanov Baruj
Funding agency: Instituto de Salud Carlos III
Funding: 177100
Reference: DTS15/00151
Duration: 01/01/2016 - 30/06/2018

Diabetis i Metabolisme (GRC)

IP: Rafael Simó Canonge
Collaborators: Josep A Villena Delgado, Carles Zafon Llopis, Cristina Hernández Pascual, David Martinez Selva, Andreea Ciudin Mihai, Lorena Ramos Pérez, Rosa Burgos Peláez, Olga Simó Servat, Patricia Bogdanov Baruj
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 40000
Reference: 2014 SGR 270
Duration: 01/01/2014 - 31/12/2016

Neuroprotección en la retinopatía diabética: una nueva estrategia terapéutica

IP: Rafael Simó Canonge
Collaborators: Rosario Pardo Diaz, Patricia Bogdanov Baruj, Laura Natalia Distefano
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 187200
Reference: SAF2012-35562
Duration: 01/01/2013 - 31/12/2015

Related news

The work represents a paradigm shift in the clinical approach to this chronic, multifactorial disease, based on the clinical context of each patient and not only on weight loss.

The results of a phase 3 clinical trial show that orforglipron reduces body weight by an average of 11% and improves cardiovascular risk factors.

Dr. Maria Llorián-Salvador, from the Diabetes and Metabolism Research Group at VHIR, is leading this project to identify new therapies for this inherited disease that causes progressive vision loss.

Related professionals

Joaquin Lopez Soriano

Joaquin Lopez Soriano

P Management and Admin. Project manager
Clinical Trials Management Unit
Clinical Research Development Directorate
Read more
Ana Gallego Cortes

Ana Gallego Cortes

Postdoctoral researcher
Infectious Diseases
Read more
José Antonio Arranz  Amo

José Antonio Arranz Amo

Postdoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Alba Maria Jiménez Masip

Alba Maria Jiménez Masip

Predoctoral researcher
Liver Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.